97 completed, 53 recruiting, 37 unknown, 15 not yet recruiting. 56 Phase 2, 40 Phase 3, 28 Not applicable, 27 Phase 4, 15 Phase 1.
Follow Nephrosis: new trials by email Literature Review of Nephrosis trials Research Report on Nephrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| Effects of Meal Macronutrients on Postprandial Lipids High carb then high fat breakfast, High fat then high carb breakfast - Nephrotic Syndrome, Lipodystrophy | Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 100 | 2026-11-15 | 2026-11-10 |
| Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays - Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 12 | 2026-10-31 | 2026-09-10 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| Clinical Prediction Model for Disease Progression in Primary Membranous Nephropathy Membranous Nephropathy, Nephrotic Syndrome | Not yet recruiting | Assiut University | 128 | 2026-08-20 | 2026-09-02 | |
| Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome Zuberitamab, standard corticosteroid treatment - Nephrotic Syndrome | Phase 3 | Not yet recruiting | Children's Hospital of Fudan University | 120 | 2026-08-20 | 2026-08-14 |
| A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD) Obinutuzumab Injection, Predniso(lo)ne - Minimal Change Disease (MCD) | Phase 2 | Recruiting | Medical University Innsbruck | 48 | 2026-07-13 | 2026-08-17 |
| Comparison of Efficacy and Safety of Albumin Versus Fresh Frozen Plasma in Managing Diuretic Resistant Edema in Children With Idiopathic Nephrotic Syndrome. Human Albumin 20%, Fresh Frozen Plasma - Idiopathic Nephrotic Syndrome (INS) | Not applicable | Not yet recruiting | Qamar Shafiq | 56 | 2026-07-05 | 2026-07-06 |
| RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases RD06-05 CART Cell Infusion - Autoimmune Diseases, SLE - Systemic Lupus Erythematosus | Early Phase 1 | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 30 | 2026-07-01 | 2026-06-29 |
| Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Everest Medicines (China) Co.,Ltd. | 45 | 2026-05-20 | 2026-08-05 |
| CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease QT-219CX - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-05-08 | 2026-05-14 |
| Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-04-01 | 2026-04-02 |
| Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome Obinutuzumab - Nephrotic Syndrome，Idiopathic | Phase 2 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 10 | 2026-02-01 | 2026-01-26 |
| A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines Use of an electronic digital Application - Chronic Kidney Disease, Proteinuria | Not applicable | Recruiting | St. James's Hospital, Ireland | 80 | 2026-01-14 | 2026-05-01 |
| Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study Conventional 24-week glucocorticoid regimen, short-term course (12 week) glucocorticoid regimen - Idiopathic Nephrotic Syndrome | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 224 | 2026-01-01 | 2025-09-03 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2025-12-01 | 2026-02-03 |
| Dupilumab Therapy in Nephrotic Syndrome in Children Dupilumab, Placebo, Co-intervention of Prednisolone wean during randomised controlled phase - Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent | Phase 2 | Recruiting | National University Hospital, Singapore | 66 | 2025-11-27 | 2025-12-05 |
| SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome Dapagliflozin, Empagliflozin, Standard Therapy - Nephrotic Syndrome | Phase 2 / Phase 3 | Recruiting | Mansoura University | 75 | 2025-11-15 | 2026-06-09 |
| Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis ANCA Associated Vasculitis, Extramembranous Glomerulopathy | Recruiting | Assistance Publique - Hôpitaux de Paris | 146 | 2025-11-03 | 2026-06-30 | |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis BAT4406F, Placebos - Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 192 | 2025-10-26 | 2026-04-03 |
Showing 20 of 231. Sign in to see all of them.
Nephrotic Syndrome (183) · Nephrosis, Lipoid (75) · Glomerulosclerosis, Focal Segmental (51) · Proteinuria (35) · Kidney Diseases (29) · Glomerulonephritis, Membranous (28) · Glomerulonephritis, IGA (18) · Renal Insufficiency, Chronic (16) · Glomerulonephritis (14) · Diabetic Nephropathies (13) · Macular dystrophy, corneal type 1 (10) · Autoimmune Diseases (7) · Nephritis (6) · Edema (4)
Female Urogenital Diseases (231) · Female Urogenital Diseases and Pregnancy Complications (231) · Male Urogenital Diseases (231) · Urogenital Diseases (230) · Urologic Diseases (229) · Kidney Diseases (202) · Nephritis (76) · Glomerulonephritis (67) · Pathological Conditions, Signs and Symptoms (61) · Immune System Diseases (46) · Signs and Symptoms (41) · Autoimmune Diseases (36) · Urination Disorders (36) · Urological Manifestations (36)
Rituximab (24) · Prednisone (15) · Tacrolimus (12) · Prednisolone (11) · Mycophenolic Acid (9) · Adrenal Cortex Hormones (7) · Adrenocorticotropic Hormone (5) · Cyclophosphamide (4) · Atorvastatin (3) · Cyclosporine (3) · Furosemide (3) · Standard of Care (3) · Steroids (3) · apixaban (3) · dapagliflozin (3)
Assistance Publique - Hôpitaux de Paris (13) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (13) · The Children's Hospital of Zhejiang University School of Medicine (10) · Istituto Giannina Gaslini (7) · Mario Negri Institute for Pharmacological Research (7) · University of Michigan (6) · Children's Hospital of Fudan University (5) · Goldfinch Bio, Inc. (4) · Northwell Health (4) · Seoul National University Hospital (4) · Ain Shams University (3) · Assiut University (3) · Centre Hospitalier Universitaire de Nice (3) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (3) · Nilratan Sircar Medical College (3)
United States (66) · China (39) · Italy (25) · France (24) · Canada (8) · Egypt (8) · South Korea (8) · Germany (7) · Poland (7) · United Kingdom (7) · Denmark (5) · India (5) · Spain (5) · Turkey (Türkiye) (5) · Belgium (4)
Gianmarco Ghiggeri, MD (4) · Giuseppe Remuzzi, MD (4) · Jeffrey B Kopp, M.D. (3) · Matthias Kretzler, MD (3) · Biswanath Basu (2) · Daniel Crona, PharmD, PhD (2) · Debbie Gipson, MD (2) · Gian Marco Ghiggeri, MD (2) · Halil Yazici, MD (2) · Jianhua Mao, MD (2) · Julie D Saba, MD, PhD (2) · Meryl A Waldman, M.D. (2) · Qian Shen (2) · Vincent Guigonis, MD (2)
PMID 39513526, PMID 35230699, PMID 38724717, PMID 40337980, PMID 35224732, PMID 34778952, PMID 36223961, PMID 36456193, PMID 37678236, PMID 39171624, PMID 41630898, PMID 12387184, PMID 12444222, PMID 12478360, PMID 12584259, PMID 12761235, PMID 12763891, PMID 12814058, PMID 12944064, PMID 14655180, PMID 15327385, PMID 15734130, PMID 15882260, PMID 15954915, PMID 16228184, PMID 16267158, PMID 16481888, PMID 16935903, PMID 16961774, PMID 17489822, PMID 17554116, PMID 17554565, PMID 17636340, PMID 17681166, PMID 17855645, PMID 17942957, PMID 17989649, PMID 19210218, PMID 20391507, PMID 21494860, PMID 21626222, PMID 22109742, PMID 22156539, PMID 22213727, PMID 22237399, PMID 22334613, PMID 22578956, PMID 22722778, PMID 22734031, PMID 22744715
U54DK083912 (3), 2018 (2), 2025 (2), R01DK131091 (2), R01DK141114 (2), 2008 (1), 2009 (1), 2015 (1), 2017 (1), 2019 (1), 2023 (1), 5RC2DK122397 (1), K23DK093556 (1), K23DK118189 (1), P30DK081943 (1)